SCHEMBL2192163

SCHEMBL2192163

Nc1cccc(Oc2ccc3nc(NC(=O)C4CC4)oc3c2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 7/20 0.45
MTNR1A P48039 1/20 0.45
MTNR1B P49286 1/20 0.45
HPGD P15428 1/20 0.39
KDR P35968 3/20 0.39
AURKA O14965 1/20 0.39
PDGFRB P09619 1/20 0.39
KIT P10721 1/20 0.39
FLT1 P17948 1/20 0.39
ALDH1A1 P00352 1/20 0.39
JAK2 O60674 1/20 0.39
MEN1 O00255 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
GFER P55789 1/20 0.39
KMT2A Q03164 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
AAK1 Q2M2I8 1/20 0.39
RIPK1 Q13546 1/20 0.39
RIPK3 Q9Y572 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2194742 0.86 ABL1 (0.47) ABL1MTNR1AMTNR1BALDH1A1JAK2
SCHEMBL2196644 0.85 KDR (0.47) ABL1MTNR1AMTNR1BKDRAURKA
SCHEMBL2189841 0.85 NPC1 (0.47) ABL1MTNR1AMTNR1BKDRALDH1A1
SCHEMBL2191687 0.81 ABL1 (0.42) ABL1MTNR1AMTNR1BKDRAURKA
SCHEMBL2190270 0.77 NPC1 (0.64) ABL1KDRAURKAPDGFRBKIT
SCHEMBL2192527 0.77 KDR (0.55) ABL1KDRPDGFRBKITFLT1
SCHEMBL2190668 0.77 SMN1; SMN2 (0.57) ABL1MTNR1AMTNR1BKDRNPC1
SCHEMBL2193891 0.76 MTNR1A (0.47) ABL1MTNR1AMTNR1BHPGDKDR
SCHEMBL2195154 0.74 BRAF (0.64) KDRALDH1A1KMT2A
SCHEMBL2194095 0.74 BRAF (0.57) KDRAURKAPDGFRBKITFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2181987-B9 2-Carbonylaminobenzothiazoles and their use for the prophylaxis and treatment of cancer TAKEDA PHARMACEUTICAL (JP) 2014-09-03 EP disclosed
EP-2181987-B1 2-Carbonylaminobenzothiazoles and their use for the prophylaxis and treatment of cancer TAKEDA PHARMACEUTICAL (JP) 2014-03-05 EP disclosed
US-8324395-B2 Heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-12-04 US disclosed
US-20110172245-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-07-14 US disclosed
EP-2181987-A1 HETEROCYCLIC COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-05-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172245-A1 HETEROCYCLIC COMPOUND AND USE THEREOF BRAF, NRAS, RAF1 ABL1 102/4885MTNR1A 4761/4885MTNR1B 4522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.